[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT00899405":3,"trial-entities:NCT00899405":71,"trial-summary:NCT00899405":75},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":25,"interventions":28,"primary_outcomes":29,"secondary_outcomes":33,"sex":34,"minimum_age":35,"maximum_age":23,"healthy_volunteers":36,"eligibility_criteria":37,"std_ages":41,"locations":44,"central_contacts":60,"overall_officials":62,"references":66,"see_also_links":67},"NCT00899405","225287","Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer","EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood","RECRUITING","2034-05","2026-06","2026-06-25","2004-05-19","University of California, Davis","OTHER",true,"RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.\n\nPURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.","OBJECTIVES:\n\n* Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.\n* Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.\n\nOUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.",[19],"Lung Cancer",[21],"lung cancer","OBSERVATIONAL",null,[],{"count":26,"type":27},800,"ESTIMATED",[],[30],{"measure":31,"timeFrame":32},"Mutational status of the EGFR pathway","up to 1 year",[],"ALL","18 Years",false,{"inclusion":38,"exclusion":39,"raw_text":40},[],[],"DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed lung cancer\n\nPATIENT CHARACTERISTICS:\n\n* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* May have received prior EGFR inhibitors",[42,43],"ADULT","OLDER_ADULT",[45],{"facility":46,"status":8,"city":47,"state":48,"zip":49,"country":50,"contacts":51,"geoPoint":57},"University of California Davis Cancer Center","Sacramento","California","95817","United States",[52],{"name":53,"role":54,"phone":55,"email":56},"Office of Clinical Research","CONTACT","916-382-6970","OCRReferral@health.ucdavis.edu",{"lat":58,"lon":59},38.58157,-121.4944,[61],{"name":53,"role":54,"phone":55,"email":56},[63],{"name":64,"affiliation":13,"role":65},"Jonathan Riess, MD","PRINCIPAL_INVESTIGATOR",[],[68],{"label":69,"url":70},"Learn more or sign up for the study here!","https:\u002F\u002Fstudypages.com\u002Fs\u002Fstudying-tumor-tissue-samples-and-blood-samples-to-learn-more-about-dna-changes-in-patients-with-lung-cancer-705725\u002F",{"nct_id":4,"conditions":72,"biomarkers":74},[73],"Lung Carcinoma",[],{"nct_id":4,"found":15,"summary":76,"prompt_version":86},{"design":77,"status":78,"heading":79,"summary":80,"follow_up":81,"word_count":82,"commitments":83,"compensation":84,"drugs_mentioned":85},"This is an observational study, meaning researchers will collect and analyze samples without giving new treatments. It plans to include 800 participants.","completed","Studying DNA Changes in Lung Cancer Tissue and Blood Samples","This study is looking at tumor tissue and blood samples from people with lung cancer to understand changes in their DNA. Researchers want to learn more about a specific pathway called EGFR (Epidermal Growth Factor Receptor) and how mutations (changes) in this pathway relate to how patients do over time. You can join if you are 18 or older and have lung cancer that has been confirmed by a doctor. You may have already received treatments for EGFR. The study aims to enroll 800 participants. The current recruitment status is unclear.","The mutational status of the EGFR pathway will be measured for up to 1 year.",91,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]